Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
This review collected human studies on how cannabidiol (CBD) is absorbed, distributed, and cleared. From 792 records, 24 studies reported pharmacokinetic (PK) data. Results varied by how CBD was given and by formulation. For example, smoking produced faster and higher blood levels than oral or oromucosal routes. The authors concluded…
Cannabis makes more than 120 “minor” cannabinoids that appear in smaller amounts than THC and CBD and come from a parent compound called cannabigerolic acid (CBGA). Early lab and clinical work shows these minor cannabinoids can activate or block many biological targets (for example CB1 and CB2 receptors, TRP channels,…
Cannabidiol (CBD) is a non‑intoxicating chemical from cannabis that affects brain signaling. It is used in one FDA‑approved medicine (Epidiolex) for some severe seizure disorders. Research suggests CBD may help with seizures, psychosis, anxiety, pain, inflammation, sleep, and some brain disorders, but the evidence is still incomplete. CBD taken by…
This review looked at 47 completed clinical trials of cannabinoids (mainly THC and CBD) for brain and nerve conditions. Some trials showed benefits for symptoms like spasticity in multiple sclerosis and for certain forms of epilepsy, but results for pain were mixed. The authors say the evidence is promising but…
